First-in-class therapy approved for schizophrenia
European Pharmaceutical Review
SEPTEMBER 27, 2024
The US Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) for schizophrenia in adults. BMS strikes $14bn deal for Karuna Therapeutics The post First-in-class therapy approved for schizophrenia appeared first on European Pharmaceutical Review.
Let's personalize your content